Binex filed IND for a new colon cancer drug.

Published: 2004-03-05 06:56:00

Updated: 2004-03-05 06:56:00

Binex (President: Lee Baek-cheon) announced that an investigational new drug application (IND) for DC-Vac/IR, a new colon cancer injectable drug, was submitted to KFDA on March 2.

DE-Vac/IR is a new immunological agent for the colon cancer treatment by injecting auto-immunized cells into the ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK